Speed of Increasing milk Feeds Trial

Submission date	Recruitment status
05/03/2013	No longer recruiting
Registration date 14/03/2013	Overall study status Completed
Last Edited	Condition category
23/08/2021	Pregnancy and Childbirth

- [X] Prospectively registered
- [X] Protocol
- [] Statistical analysis plan
- [X] Results
- [] Individual participant data

Plain English summary of protocol

Background and study aims

Survival of preterm infants has increased greatly over the years, so a major aim now is to improve the long-term outlook for these infants and to avoid serious complications. The way infants are fed in early life affects short- and long-term health and survival. Because the bowels of preterm infants have not matured, they cannot digest large volumes of milk feeds straight away. Until the gut matures, nutrition is provided by intravenous drip while the amount of milk given is gradually increased over time. Increasing the amount of milk rapidly may increase the risk of gut complications. Increasing the amount of milk given more slowly means that intravenous nutrition is needed for longer; there is an associated risk of infection proportional to the time the intravenous line is present in the bloodstream of these infants. Despite the importance of milk feeding preterm infants, there have been few studies to inform how best to balance these risks, and what the best way to increase feeds in these infants is - this study sets out to address this missing information. The study will compare two different rates of increase of milk feeds, one faster and one slower, both within rates currently used in UK neonatal units. The study aims to find out if either rate gives better outcomes for the infants. Investigators will measure a variety of outcomes, such as survival without disability, infection, bowel problems, growth and long-term physical and mental development, as well as the impact on families and the NHS, including costs. The study will be led by an established team of researchers who have run similar studies before, and will use an established network of neonatal units that have taken part in previous studies.

Who can participate?

The study will recruit 2800 very preterm (<32 weeks) or VLBW (<1,500 g) infants from 58 neonatal units within the UK and Ireland over 3 years.

What does the study involve?

With informed consent from parents, infants will be randomly allocated to receive either faster (30 ml/kg/day) or slower (18 ml/kg/day) increases in milk feed volumes. As well as assessing the effect of a faster feeding increment on the risk of severe or moderate disability, the study will also compare the rate of serious infection and necrotising enterocolitis [portions of the bowel undergo necrosis (tissue death)], the time taken to reach full milk feeds, the duration of nutrition is provided by intravenous drip, growth, and the length of hospital stay between the

two groups. Infants will be followed up at 2 years of age via a questionnaire which will be posted to the parents. Finally, an economic evaluation will be undertaken to determine whether faster feeding advancement is a cost-effective treatment.

What are the possible benefits and risks of participating?

There will be no immediate direct benefit to those taking part in the study; however, there should be benefits to future very preterm or VLBW babies as the results of the study are likely to influence NHS neonatal feeding policy and practice. As both the study rates of increase of milk feeds (faster and slower) are within rates currently used in UK neonatal units, there is no difference in risk between feeding regimens administered as part of the study and those administered as part of standard clinical care.

Where is the study run from?

SIFT is run from the National Perinatal Epidemiology Unit Clinical Trials Unit at the University of Oxford (UK).

When is the study starting and how long is it expected to run for? Recruitment started in summer 2013 and finished in summer 2015. Follow-up will start 2 years after the first infants are recruited (summer 2015) and continue until 2 years after the last infants are recruited (summer 2015).

Who is funding the study? NIHR Health Technology Assessment Programme - HTA (UK)

Who is the main contact? Chief Investigator, Jon Dorling: Jon.Dorling@iwk.nshealth.ca Trial Coordinator: sift@npeu.ox.ac.uk

Study website https://www.npeu.ox.ac.uk/sift

Contact information

Type(s) Scientific

Contact name Mr Oliver Hewer

Contact details NPEU Clinical Trials Unit Nuffield Department of Population Health University of Oxford Old Road Campus Oxford United Kingdom OX3 7LF

sift@npeu.ox.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number NCT01727609

Secondary identifying numbers HTA 11/01/25

Study information

Scientific Title

A multi-centre randomised controlled trial of two speeds of daily increment of milk feeding in very preterm or very low birth weight infants

Acronym

SIFT

Study objectives

It is hypothesised that the proportion of very preterm (<32 weeks) or very low birth weight [VLBW] (<1,500 g) infants surviving without moderate or severe disability at 24 months post menstrual age will be greater in the faster (30 ml/kg/day) versus slower (18 ml/kg/day) increasing milk feed regimen.

Ethics approval required Old ethics approval format

Ethics approval(s) NRES Committee East Midlands - Nottingham 2, 31/01/2013, ref: 13/EM/0030

Study design Phase III multi-centre open-label randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Prevention

Participant information sheet Patient information can be found at: https://www.npeu.ox.ac.uk/sift/parent-resources

Health condition(s) or problem(s) studied

Neonatal feeding, preterm infants, very low birth weight infants, necrotising enterocolitis, lateonset invasive infection

Interventions

The study will recruit 2800 very preterm or VLBW from 58 neonatal units within the UK and Ireland over 3 years.

Infants will be randomly allocated to receive either faster (30 ml/kg/day) or slower (18 ml/kg /day) increases in milk feed volumes. Until discharge they will be monitored for late-onset invasive infection, necrotising enterocolitis, time taken to reach full milk feeds, growth, duration of parenteral feeding, length of hospital stay, and length of time in intensive care.

They will be assessed for moderate or severe disability at 24 months post menstrual age.

Intervention Type

Other

Phase

Phase III

Primary outcome measure

Moderate or severe disability at 24 months post menstrual age

Secondary outcome measures

Current secondary outcome measures as of 28/04/2016:

1. Survival to discharge home

2. Incidence of microbiologically-confirmed or clinically suspected late-onset infection from trial entry until hospital discharge

- 3. NEC (Bell stage 2 or 3) from trial entry
- 4. Time taken to reach full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
- 5. Growth (weight and head circumference) when discharged home
- 6. Duration of parenteral feeding
- 7. Length of time in intensive care
- 8. Length of hospital stay
- 9. Diagnosis of cerebral palsy by a doctor or other health professional (parent reported)

Previous secondary outcome measures:

1. Incidence of microbiologically-confirmed or clinically suspected late-onset invasive infection from trial entry until hospital discharge

- 2. Incidence of necrotising enterocolitis (NEC) [Bell stage 2 or 3]
- 3. Time taken to reach full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
- 4. Growth (weight and head circumference) at discharge
- 5. Duration of parenteral feeding before discharge
- 6. Length of time in intensive care
- 7. Length of hospital stay

Overall study start date

01/02/2013

Eligibility

Key inclusion criteria

1. Gestational age at birth <32 weeks, or birth weight <1,500 g

2. The infant is receiving ≤30 ml/kg/day of milk at randomisation

3. Written informed parental consent is obtained

To ensure the widest applicability to preterm infants across the UK, those exclusively breast milk fed, formula milk fed, or receiving mixed feeds will be included.

Participant type(s)

Patient

Age group Neonate

Sex Both

Target number of participants 2800

Total final enrolment 2804

Key exclusion criteria

Infants with a severe congenital anomaly
Infants who, in the opinion of the treating clinician, have no realistic chance of survival
Infants who are unlikely to be traceable for follow-up at 24 months of age (for example, infants of non-UK residents)

Date of first enrolment 01/06/2013

Date of final enrolment 31/05/2015

Locations

Countries of recruitment England

Ireland

United Kingdom

Study participating centre NPEU Clinical Trials Unit Oxford United Kingdom OX3 7LF

Study participating centre 58 other sites United Kingdom

Sponsor information

Organisation University of Oxford (UK)

Sponsor details

Clinical Trials and Research Governance Joint Research Office Block 60 Churchill Hospital Old Road, Headington Oxford England United Kingdom OX3 7LE

Sponsor type University/education

Website http://www.ox.ac.uk/

ROR https://ror.org/052gg0110

Funder(s)

Funder type Government

Funder Name Health Technology Assessment Programme Alternative Name(s) NIHR Health Technology Assessment Programme, HTA

Funding Body Type Government organisation

Funding Body Subtype National government

Location United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date 10/05/2019

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	28/01/2017		Yes	No
<u>Results article</u>	results	10/10/2019	10/10/2019	Yes	No
<u>Results article</u>	results	01/04/2020	29/04/2020	Yes	Νο
<u>Results article</u>	Study Within A Trial (SWAT)	21/08/2021	23/08/2021	Yes	No
HRA research summary			28/06/2023	No	No